Effects of N-linked glycosylation of the fusion protein on replication of human metapneumovirus in vitro and in mouse lungs.

Effects of N-linked glycosylation of the fusion protein on replication of human metapneumovirus in vitro and in mouse lungs.
复制标题

DOI:
10.1099/vir.0.030049-0
复制
发表时间:
2011-07
期刊:
The Journal of general virology
影响因子:
--
通讯作者:
Jinhui Zhang;Y. Dou;Junfeng Wu;Wei-wei She;L. Luo;Yao Zhao;Ping Liu;Xiaodong Zhao
Jinhui Zhang;Y. Dou;Junfeng Wu;Wei-wei She;L. Luo;Yao Zhao;Ping Liu;Xiaodong Zhao
中科院分区:
其他
文献类型:
--
作者:
Jinhui Zhang;Y. Dou;Junfeng Wu;Wei-wei She;L. Luo;Yao Zhao;Ping Liu;Xiaodong Zhao

文献摘要

相似文献

The fusion (F) protein is an important membrane glycoprotein necessary for cellular entry and replication of human metapneumovirus (hMPV). Selective prevention of N-linked glycosylation may compromise the catalytic and fusion functions of the F protein. By using site-directed mutagenesis and reverse genetics, recombinant mutant viruses lacking one or two N-linked glycosylation sites in the F protein were constructed. M1, which lacked glycosylation at position 57 of the F protein, had slightly compromised replication, whereas M2 and M4, which lacked glycosylation at position(s) 172 or 57 and 172, respectively, showed profound impairment of replication when compared with wild-type (WT) NL/1/00-GFP virus in both Vero E6 cells and mouse lungs. M2 was less fit than WT virus in vitro and in immunocompromised mouse lungs. The F proteins of WT and mutant viruses were similarly expressed on the infected cell membrane, while the activated fusion protein subunits, F1 of M2 and M4, were produced in lower quantities compared with those of WT and M1 virus. The mutated viruses lacking N-linked glycosylation at position 353, either individually or together with other sites, could not be recovered. Thus, N-linked glycosylation may be involved in the catalysis of the fusion protein from F0 to F1 and F2, which is critical for fusion function. Strategies targeting N-linked glycosylation may be helpful for developing attenuated live vaccines or antiviral drugs for hMPV.